## REMARKS/ARGUMENTS

Claims 1-6, 8, 10, 12, and 14 are canceled.

Claims 15-18 are new.

Support for each new and amended claim is found at the originally filed claims and throughout the specification.

No new matter is believed to have been added.

The objections to Claims 8-14 are obviated by the cancellation of Claims 8, 10, 12, and 14, and the amendment of Claims 9, 11, and 13.

The anticipation rejection of Claims 7-14, as being unpatentable over <u>Koyanagi</u>, is respectfully traversed, because <u>Koyanagi</u> does not describe or suggest all of the features of the present claims. The rejection of Claims 8, 10, 12, and 14 is obviated by cancellation of these claims.

Present Claim 8 has a feature that the novolac type epoxy resin has an epoxy equivalent of 100 to 300 g/eq. Koyanagi does not describe or suggest this feature.

Koyanagi, at Example 1, paragraph 27, describes an epoxy equivalent of 353 g/eq, however, Koyanagi does not describe or suggest an epoxy equivalent of 100 to 300 g/eq, a feature of present Claim 1. On this basis alone, withdrawal of the anticipation rejection is requested.

Additionally, a separate feature of present Claim 1 is (A) a novolac type epoxy resin represented by the following general formula (1), (2), or (3). This feature is not described or suggested by <u>Koyanagi</u>.

Compound (A) of Koyanagi, in contrast to Compound A (the novolac type expoy resin) of present Claim 1, is a reaction product of an epoxy compound (a) with a compound (b) containing one carbonyl group and two hydroxyl groups and with a polybasic anhydride (c) (see Claim 1 and paragraph 7 of Koyanagi). While epoxy compound (a) can be a phenol novolak mold epoxy resin in Koyanagi (see paragraph8 of Koyanagi), this phenol novolak

Application No. 10/593,815
Reply to Office Action of October 3, 2007

mold epoxy resin is reacted with a compound (b) containing one carbonyl group and two

hydroxyl groups and a polybasic anhydride (c) to form Koyanagi's Compound A.

Thus, compound A of present Claim 1 is different than Compound A of Koyanagi, and Koyanagi does not describe or suggest Compound A of present Claim 1 used in combination with Compounds B and C.

Withdrawal of the anticipation rejection is requested.

Applicants submit the present application is now in condition for allowance. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C. Norman F. Oblon

Charles J. Andres, Jr., Ph.D.

Attorney of Record Registration No. 57,537

 $\begin{array}{c} \text{Customer Number} \\ 22850 \end{array}$ 

Tel: (703) 413-3000 Fax: (703) 413 -2220 (OSMMN 08/07)